Table 6.
Target | Primer | Sequence |
---|---|---|
SLP-76 | Forward
Reverse |
5′-TCTTGACCGAGAGCCCTTCAT-3′
5′-TCTTTCGTGTCTGTCCATGGC-3′ |
SLAP | Forward
Reverse |
5′-GAATCTTCCGTCTTCCCAACAA-3′
5′-CACAGCATAGACCATCAGCCAC -3′ |
SHIP-1 | Forward
Reverse |
5′-TCTGCAGAGGTTGTTTGACCA-3′
5′-CAATTGGCTGAGTTTGGCAA-3′ |
CD18 | Forward
Reverse |
5′-GTTTCAGACAGAGGTCGGCAA-3′
5′-GCCAATTTCCTCCGGACAT -3′ |
Jag1 | Forward
Reverse |
5′-CACTTATTGCTGCGGTTGCA -3′
5′AAGCAACAGACCCAAGCCACT-3′ |
Epherin B3 | Forward
Reverse |
5′CTGCTGCTGTTAGGTTTTGCG -3′
5′CCGATCTGAGGATAAAGCACGT -3′ |
Mylk | Forward
Reverse |
5′-AACATCTTTGGCACACCCGA-3′
5′-CGCTCAGGAGGATGTAGGTGAT -3′ |
Myl6* | Forward
Reverse |
5′-AGGCACCTGCAAAATCCCA-3′
5′-CAGCTCAAAGGCCTCTCTGAAT-3′ |
GRAIL | Forward
Reverse |
5-GCAGGAAGCAGAGGCAGTTAAA-3′
5′-GCACACAGCACAGCTATCTCCA -3′ |
β-Actin | Forward
Reverse |
5′-CAACGAGCGGTTCCGATG -3′
5′-GCCACAGGATTCCATACCCA -3′ |
Myl6 (Myosin light chain polypeptide 6; Accession AI450945) is the product of a structural gene that was only expressed in non-anergic cells (1.4SD above background; Supplemental Table 2). All other designations are referred to in the text.